This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Intravenous thrombolytic therapy

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Four phase 3 trials of intravenous t-PA for ischaemic stroke have been reported. The FDA of North America approved this therapy on the basis of the National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study (NINDS rt-PA Stroke Study). Other large trials have been less favourable including ECASS I, ECASS II and ATLANTIS.

Three trials of streptokinase have been initiated but halted because of excess mortality and poor outcome.


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.